The increasing threat of Pseudomonas aeruginosa high-risk clones.

By A. Oliver, X. Mulet, C. López-Causapé, C. Juan. Drug resistance updates, 2015

600 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Structure-Based Prototype Peptides Targeting the Pseudomonas aeruginosa Type VI Secretion System Effector as a Novel Antibacterial Strategy (2017, background): “…TplE-TplEi interaction, toxin-antitoxin, antibacterial peptide INTRODUCTION Pseudomonas aeruginosa is one of the most common nosocomial infectious bacteria that causes significant morbidity and mortality in immunocompromised patients or intensive care unit (ICU) patients (Oliver et al., 2015).”
ESKAPE pathogens: antimicrobial resistance, epidemiology, clinical impact and therapeutics (2024, unknown): “Antimicrobial resistance — in particular, that mediated by trans-ferrable resistance determinants — is a feature of several high-risk clonal groups, including ST235 (clade B), ST111 (clade A) and ST175 (clade A), among others 135 .”
Pseudomonas aeruginosa Lifestyle: A Paradigm for Adaptation, Survival, and Persistence (2017, background): “Particularly, chromosomal expression and production of AmpC confers low level resistance to aminopenicillins and most cephalosporins because these antibiotics strongly induce the production of AmpC which consequently hydrolyzes these substrates (Oliver et al., 2015).”
Epidemiology and Treatment of Multidrug-Resistant and Extensively Drug-Resistant Pseudomonas aeruginosa Infections (2019, background): “aeruginosa poses a threat to global public health that needs to be studied and managed with urgency and determination (3).”